The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
21 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Signed and dated informed consent form
Good general health
Male or female subjects aged >21 years old
Availability for the 9 week duration of the study
Chronic periodontal disease on natural teeth characterized by the presence of at least 2 teeth with periodontal pockets of 5-9 mm in depth (potential target teeth) demonstrating bleeding on probing without involving the apex of the tooth and confirmed by dental X-ray.
Females of childbearing potential must be non-pregnant and non-lactating at entry and agree to use an adequate method (Oral or parenteral hormonal contraceptive; Intrauterine device; barrier and spermicide) of birth control during the study.
An existing aggressive periodontitis.
Presence of oral local mechanical factors that could (in the opinion of the investigator) influence the outcome of the study.
Presence of orthodontic appliances, or any removable appliances, that impinge on the tissues being assessed.
Soft or hard tissue tumours of the oral cavity.
Presence of dental implant adjacent to target tooth.
Presence of more than 2 adjacent periodontal pockets on the same potential target tooth.
Periodontal pockets of more than 9 mm in depth, and/or with class 2 or 3 furcation involvement, on the potential target tooth.
Systemic antibiotic therapy or periodontal/mechanical/local delivery therapy within 6 weeks prior to study entry and throughout the study duration.
History of allergy to chlorhexidine, flurbiprofen or to other non-steroidal anti-inflammatory drugs (NSAIDs).
Subjects taking Phenytoin, calcium channel blockers drugs (CCBs) and/or cyclosporine, which might influence the pattern of tissue response.
Subjects treated with non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to entry into the study and throughout the study duration.
Presence of the following conditions: Type 1 diabetes, major recurrent aphtae, stomatitis, abscesses and related oral pathologies.
The presence of any medical or psychiatric condition that in the opinion of the investigator could affect the successful participation of the subject in the study.
Subject participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.
Subject uses chlorhexidine oral rinses/ mouthwashes on a regular basis.
Keywords provided by Dexcel Pharma Technologies Ltd.:
Subjects, age>21, with Chronic periodontal disease on natural teeth characterized by the presence of at least 2 teeth with periodontal
pockets of 5-9 mm in depth demonstrating bleeding on probing without involving the
apex of the tooth and confirmed by dental X-ray.